A functional immune-based platform for donor-recipient matching in faecal microbiota transplantation for inflammatory bowel disease

{"BACKGROUND:":[0],"Faecal":[1],"microbiota":[2,29,42,75,93,107],"transplantation":[3],"(FMT)":[4],"shows":[5],"variable":[6],"efficacy":[7],"in":[8,55],"inflammatory":[9],"bowel":[10],"disease":[11],"(IBD),":[12],"and":[13,76,97,188,211,246,252],"current":[14],"donor":[15,28,41,74],"selection":[16],"strategies":[17],"rely":[18],"primarily":[19],"on":[20,157],"microbiome":[21],"characteristics,":[22],"while":[23],"host":[24],"immune":[25,38,71,115,141,145,183],"responses":[26,39,146],"to":[27,40,46,69,92,100,164,172],"remain":[30],"largely":[31],"unexplored.":[32],"Here,":[33],"we":[34,160],"investigated":[35],"whether":[36],"recipient-specific":[37],"could":[43],"be":[44,213],"leveraged":[45],"develop":[47],"a":[48,60,127,170,191],"personalised":[49,187],"donor-recipient":[50,166,175,182,209],"matching":[51],"strategy":[52],"for":[53],"FMT":[54,195,218],"IBD.":[56,79],"METHODS:":[57],"We":[58],"developed":[59,161],"proof-of-concept":[61,204],"(POC)":[62],"assay,":[63],"termed":[64],"Gut":[65],"Microbiota-Leukocyte":[66],"Reaction":[67],"(GMLR),":[68],"assess":[70],"compatibility":[72,167,184],"between":[73],"recipients":[77],"with":[78,113,152],"Lamina":[80],"propria":[81],"mononuclear":[82],"cells":[83],"isolated":[84],"from":[85,94],"intestinal":[86],"biopsies":[87],"were":[88,103,147],"exposed":[89],"ex":[90,202],"vivo":[91,203],"healthy":[95],"donors,":[96],"cytokines":[98],"relevant":[99],"IBD":[101],"pathophysiology":[102],"measured.":[104],"FINDINGS:":[105],"Donor":[106],"clustered":[108],"into":[109],"distinct":[110],"groups":[111],"associated":[112],"differential":[114],"signatures,":[116],"including":[117],"significant":[118],"IL-22":[119],"induction":[120],"(p":[121,132],"=":[122,133],"0.033),":[123],"whereas":[124],"IL-17":[125],"showed":[126],"non-significant":[128],"trend":[129],"toward":[130],"reduction":[131],"0.054)":[134],"that":[135,181],"was":[136,223],"not":[137],"consistently":[138],"observed":[139],"across":[140,150],"cell":[142],"subsets.":[143],"However,":[144],"highly":[148,186],"individualised":[149],"recipients,":[151],"substantial":[153],"inter-patient":[154],"variability.":[155],"Based":[156],"these":[158],"responses,":[159],"an":[162],"algorithm":[163],"generate":[165],"scores,":[168],"providing":[169],"framework":[171],"prioritise":[173,208],"potential":[174],"pairs.":[176],"INTERPRETATION:":[177],"Our":[178],"findings":[179],"suggest":[180],"is":[185],"may":[189,206],"represent":[190],"key":[192],"determinant":[193],"of":[194,229,250],"efficacy,":[196],"challenging":[197],"the":[198,226,239,247],"\\"super-donor\\"":[199],"paradigm.":[200],"This":[201,221],"platform":[205],"help":[207],"pairs":[210],"should":[212],"prospectively":[214],"validated":[215],"against":[216],"clinical":[217],"outcomes.":[219],"FUNDING:":[220],"work":[222],"supported":[224],"by":[225],"Italian":[227,248],"Ministry":[228,249],"Health,":[230],"Associazione":[231],"Italiana":[232],"per":[233],"la":[234],"Ricerca":[235],"sul":[236],"Cancro":[237],"(AIRC),":[238],"European":[240],"Union-NextGeneration":[241],"EU":[242],"(HEAL":[243],"ITALIA":[244],"project),":[245],"Education":[251],"Research":[253],"(MUR).":[254]}

Authors

Institutions

Publication Details

Journal
EBioMedicine
Published
2026-09-07
DOI
https://doi.org/10.1016/j.ebiom.2026.106475
Primary Topic
Clostridium difficile and Clostridium perfringens research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

A functional immune-based platform for donor-recipient matching in faecal microbiota transplantation for inflammatory bowel disease

Federica Perillo, Martina Gilodi, Chiara Amoroso, Sara Frazzini et al.
EBioMedicine
Clostridium difficile and Clostridium perfringens research
article

A functional immune-based platform for donor-recipient matching in faecal microbiota transplantation for inflammatory bowel disease

Federica Perillo, Martina Gilodi, Chiara Amoroso, Sara Frazzini, Francesco Strati, Federica Facciotti, Flavio Caprioli, Daniele Noviello, Martina Muià, Bruna Caridi, Paola Maragno, Maurizio Vecchi
article en

Abstract

BACKGROUND: Faecal microbiota transplantation (FMT) shows variable efficacy in inflammatory bowel disease (IBD), and current donor selection strategies rely primarily on microbiome characteristics, while host immune responses to donor microbiota remain largely unexplored. Here, we investigated whether recipient-specific immune responses to donor microbiota could be leveraged to develop a personalised donor-recipient matching strategy for FMT in IBD. METHODS: We developed a proof-of-concept (POC) assay, termed Gut Microbiota-Leukocyte Reaction (GMLR), to assess immune compatibility between donor microbiota and recipients with IBD. Lamina propria mononuclear cells isolated from intestinal biopsies were exposed ex vivo to microbiota from healthy donors, and cytokines relevant to IBD pathophysiology were measured. FINDINGS: Donor microbiota clustered into distinct groups associated with differential immune signatures, including significant IL-22 induction (p = 0.033), whereas IL-17 showed a non-significant trend toward reduction (p = 0.054) that was not consistently observed across immune cell subsets. However, immune responses were highly individualised across recipients, with substantial inter-patient variability. Based on these responses, we developed an algorithm to generate donor-recipient compatibility scores, providing a framework to prioritise potential donor-recipient pairs. INTERPRETATION: Our findings suggest that donor-recipient immune compatibility is highly personalised and may represent a key determinant of FMT efficacy, challenging the "super-donor" paradigm. This ex vivo proof-of-concept platform may help prioritise donor-recipient pairs and should be prospectively validated against clinical FMT outcomes. FUNDING: This work was supported by the Italian Ministry of Health, Associazione Italiana per la Ricerca sul Cancro (AIRC), the European Union-NextGeneration EU (HEAL ITALIA project), and the Italian Ministry of Education and Research (MUR).

EBioMedicineVol. 132
University of Milan (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), University of Milano-Bicocca (IT)
Fondazione AIRC per la ricerca sul cancro ETS, Ministero della Salute
Good health and well-being
Openalex Percentile: Top 11%
Clostridium difficile and Clostridium perfringens research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.